2017 Announcements

CLINUVEL reaches agreement on German SCENESSE® pricing through AMNOG Arbitration Board

12 April 2017

CLINUVEL today announced that it had reached agreement with the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband or GKV-SV) for the treatment of erythropoietic protoporphyria (EPP) patients with CLINUVEL’s drug SCENESSE®   

CLINUVEL had been in mandatory ‘negotiation’ with GKV-SV since August 2016. Under the German Pharmaceuticals Market Reorganisation Act (AMNOG) a pricing agreement was reached after an Arbitration Board was called. The outcome of the Arbitration Board is legally binding for all state insurers (‘Krankenkassen’) in Germany. 

Download PDF for more

Go To Top